Angiogenesis inhibitors in clinical development for lung cancer

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 66-77

  Herbst, Roy S ^a   Hidalgo, Manuel ^a   Pierson, A Scott ^a   Holden, Scott N ^a   Bergen, Michael ^a   Eckhardt, S Gail ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 4 DEDIMETHYLAMINOSANCYCLINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CILENGITIDE; ENDOSTATIN; INTEGRIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PLATINUM DERIVATIVE; REBIMASTAT; SQUALAMINE;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; HUMAN; LUNG CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

EID: 0036121273     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31527     Document Type: Article

References (130)

1. Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population
2. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer
3. Chemotherapy for advanced non-small cell lung cancer
4. Cancer biology: Invasion and metastasis
5. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study
6. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
7. Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet
8. Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: Relationship to various biological factors
9. Molecular and biological properties of vascular endothelial growth factor
10. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis
11. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
12. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
13. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
14. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAb) in patients (pts) with metastatic cancer
15. Phase Ib trial of intravenous (i.v.) recombinant humanized monoclonal antibody (MAb) to vascular endothelial growth factor (rhuMAb VEGF) in combination with chemotherapy (ChRx) in patients (pts) with advanced cancer (CA): Pharmacologic and longterm safety data
16. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
17. Antitumor activity of anti-flk-1 monoclonal antibodies
18. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
19. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
20. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
21. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
22. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
23. A multicenter dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma
24. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
25. Dose finding study of cisplatin, gemcitabine, and SU5416 in patients with advanced malignancies
26. VEGF receptor tyrosine kinase inhibitors as potential anti-tumor targets
27. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
28. Phase I experience oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
29. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
30. A phase I/II study of repetitive dose Angiozyme, a ribozyme targeting the Flt-1 receptor for VEGF
31. Catecholestrogens inhibit proliferation and DNA synthesis of porcine granulose cells in vitro: Comparison with estradiol, 5 alpha-dihydrotestosterone, gonadotropins and catecholamines
32. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth
33. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol
34. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol
35. The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro
36. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and angiogenesis: Possible role of vascular endothelial growth factor
37. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines
38. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species
39. An agent that increases tumor suppressor-transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo
40. 2-Methoxyestradiol inhibits multiple metastases of human non-small cell lung cancer in nude mice with combination of systemic adenovirus-p53
41. Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol
42. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas espression
43. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells
44. 2-Methoxyestradiol does not require p53 in endothelial cells
45. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability
46. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site
47. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicines binding site
48. Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen
49. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol
50. Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion
51. An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats
52. Carcinogenicity of catechol estrogens in Syrian hamsters
53. Inhibitory effect of a primary tumor on metastasis
54. Heterologous, homologous, and autologous transplantation of human tumors
55. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
56. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
57. A recombinant human angiostatin inhibits experimental primary and metastatic cancer
58. Combined effects of angiostatin and ionizing radiation in antitumor therapy
59. Endothelial progenitor cells as putative targets for angiostatin
60. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
61. Tumour regression after endostatin therapy
62. Recombinant endostatin demonstrates safety, linear pharmacokinetics and biological effects on tumor growth factors: Results of a phase I clinical study
63. A phase I clinical trial of recombinant human endostatin (rHE) in patients with solid tumors: Pharmacokinetic, safety, and efficacy analysis
64. A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin
65. Squalamine: An aminosterol antibiotic from the shark
66. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature
67. Potential of the aminosterol, squalamine in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma
68. A phase I and pharmacokinetic (PK) study of the angiogenesis inhibitor, squalamine lactate (MSI,-1256F)
69. The role of alpha v integrins during angiogenesis
70. Regulation of cell migration by the beta subunit ectodomain of alpha(v)beta3
71. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta 5 integrins
72. Up-regulated expression of the beta3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice
73. Integrin alpha3betal can promote adhesion and spreading of metastatic breast carcinoma cells on the lymph node stroma
74. Differential adhesion of metastatic RAW117 large-cell, lymphoma cells under static or hydrodynamic conditions: Role of integrin alpha(v)beta3
75. In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization
76. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: Differential association with tumor progression and clinical prognosis
77. Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer
78. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions
79. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide
80. Prostatic carcinoma cell migration via alpha(v)beta3 integrin modulated by a focal adhesion kinase pathway
81. Phase I study of Vitaxin, an anti-angiogenic humanized monoclonal, antibody to vascular integrin alpha(v)beta3
82. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alpha(v)beta3
83. A pilot study of an angiogenesis inhibitor Vitaxin in patients with advanced leiomyosarcomas
84. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents
85. Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells
86. 5 integrins; mature results of a phase I and pharmacological study
87. Changing views of the role of matrix metalloproteinases in metastasis
88. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
89. Gelatinase A activity directly modulates melanoma cell adhesion and spreading
90. Matrix metalloproteinases and metastasis
91. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice
92. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical, application
93. Measurement of matrix metalloproteinases and tissue inhibitors of metallo-proteinases in blood and tissues. Clinical and experimental applications
94. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types
95. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
96. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal epithelial cell interactions
97. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response
98. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
99. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas
100. Overexpression of metalloproteinase inhibitor in B16F10 melanoma cells does not affect extravasation but reduces tumor growth
101. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
102. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
103. Matrix metalloproteinase inhibitors
104. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
105. Marimastat in recurrent colorectai cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
106. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
107. Phase I-II study of marimastat (BB2516) in patients (pts) with metastatic melanomas
108. Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer
109. Schedules of 5-FU and the matrix metalloproteinase inhibitor marimastat (MAR): A phase I study
110. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer
111. Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/Paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC)
112. Marimastat (BB2516): Current status and development
113. Phase I/II pharmacokinetic evaluation of marimastat in patients (pts) with advanced prostate cancer (PC): Identification of the biological active dose
114. Matrix metalloproteinase: Biologic activity and clinical implications
115. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer
116. A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma
117. Randomized double-blind placebo controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC-CTG and EORTC study
118. Promising new developments in cancer chemotherapy
119. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms
120. Matrix metalloproteinases and their inhibition in periodontal treatment
121. MMP inhibition in prostate cancer
122. Protracted daily treatment with Col-3, an oral tetracycline analog, matrix metalloproteinase (MMP) inhibitor, is feasible: A phase I pharmacokinetic and biological study
123. A phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, administered daily in patients with refractory metastatic cancer
124. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
125. Prognostic value of angiogenesis in operable non-small cell lung cancer
126. Relation of neovascularisation to metastasis of non-small-cell lung cancer
127. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
128. Anti-cancer activity of targeted pro-apoptotic peptides
129. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis